http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013519677-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C291-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C251-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C291-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C245-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-655 |
| filingDate | 2011-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013519677-A |
| titleOfInvention | Diazeniumdiolate cyclopentyl derivative |
| abstract | A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, —OH, —O—C 1-6 alkyl, ═O, or halogen; R 2 is , Hydrogen, —C (O) OR 8 , —C 6 H 5 C (O) OR 8 , — (CH 2 ) 1-2 OH, —CR 9 R 10 OH, —C (O) O (CH 2 ) 0-2 aryl, -C (O) NR 9 R 10, -C (O) SO 2 NR 9 R 10, -C 6 H 5 OR 9, -W-C (O) OR 8, -W-OR 9 , —Y, or —P (O) (OR 9 ) (OR 10 ); R 3 is hydrogen or —C 1-6 alkyl; R 4 is hydrogen, —OH, or —C (O ) be a oR 9; R 5 is hydrogen or deuterium; R 6 and R 7, independently, -C 1 to 6 alkyl, fluoro-substituted 6 alkyl, deuterated C 1-6 alkyl or - (CH 2) 1 to 2 R 11, wherein the fluoro-substituted C 1-6 alkyl, mono- or by fluoro at any carbon atom Is disubstituted and the deuterium substituted C 1-6 alkyl is mono- or disubstituted with fluoro at any carbon atom; R 8 is hydrogen, —C 1-6 alkyl, in each occurrence , Or — (CH 2 ) 2 N + (CH 3 ) 3 ; R 9 and R 10 are each independently —C 1-6 alkyl in each instance present; R 11 is —OH, -O-C 1-6 alkyl, -OCD 3 , -OC (O) OC 1-6 alkyl, -NH 2 , -C 6 H 5 , -N 3 , or W; W is 1, 2 or 5 members with 3 nitrogen atoms Ku has an unsubstituted heteroaryl ring 6- or two or three nitrogen atoms, a substituted 5- or 6-membered by R 6 or R 7 is a mono- or di-substituted at any carbon atom A heteroaryl ring; Y is N, O or S, a 5- or 6-membered heterocycle having 1, 2, 3 or 4 heteroatoms, or a stereoisomer thereof, or a pharmaceutical thereof Or a pharmaceutically acceptable salt of a stereoisomer thereof, and a method of using the compound for the treatment of hypertension. |
| priorityDate | 2010-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 436.